Marshall Wace LLP Sells 159,305 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Marshall Wace LLP lessened its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 62.0% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 97,671 shares of the medical equipment provider's stock after selling 159,305 shares during the period. Marshall Wace LLP owned approximately 0.14% of Lantheus worth $8,738,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of LNTH. Mirae Asset Global Investments Co. Ltd. grew its position in Lantheus by 47.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock valued at $1,041,000 after purchasing an additional 3,772 shares during the period. Empirical Asset Management LLC acquired a new position in shares of Lantheus during the fourth quarter valued at about $323,000. Focus Financial Network Inc. bought a new stake in shares of Lantheus during the fourth quarter worth about $292,000. Harbor Capital Advisors Inc. increased its position in shares of Lantheus by 12.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider's stock worth $13,006,000 after acquiring an additional 16,466 shares in the last quarter. Finally, World Investment Advisors LLC acquired a new stake in shares of Lantheus in the 3rd quarter worth about $60,000. Institutional investors own 99.06% of the company's stock.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of recent research reports. Truist Financial boosted their price objective on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. JMP Securities reiterated a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Finally, B. Riley dropped their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, Lantheus presently has an average rating of "Moderate Buy" and an average price target of $129.43.

Lantheus Trading Down 1.0 %

Shares of Lantheus stock opened at $99.57 on Wednesday. The business's fifty day simple moving average is $96.11 and its 200 day simple moving average is $95.36. Lantheus Holdings, Inc. has a 12 month low of $62.59 and a 12 month high of $126.89. The firm has a market capitalization of $6.82 billion, a P/E ratio of 16.57 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock worth $6,016,046 in the last quarter. Insiders own 2.00% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.